Japan Cancer Biomarkers Market Insight
Published: 29 May 2026 | Report Format: Electronic (PDF)
Japan market for cancer biomarkers has been witnessing steady growth with a CAGR of 11.37%, which is attributed to increasing incidences of cancer patients, increasing use of precision medicine, and increasing demand for early detection of cancers.
Japan Cancer Biomarkers Market Insights Forecasts to 2035
- The Japan Cancer Biomarkers Market Size Was Estimated at USD 3.5 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 11.37% from 2025 to 2035
- The Japan Cancer Biomarkers Market Size is Expected to Reach USD 10.27 Billion by 2035
Notable Insights for Japan Cancer Biomarkers Market
- According to biomarker type, genetic biomarkers made up around 44-47% of the Japan cancer biomarkers market in 2025 due to the rising use of genomic testing, precision oncology, and targeted cancer therapies.
- On the basis of cancer type, breast cancer biomarkers represented about 24-27% of the Japan cancer biomarkers market in 2025 due to the rising incidence of breast cancer and increased awareness about the diagnosis.
- The Japanese Ministry of Health, Labour and Welfare supports programs that aim to conduct cancer screening and precision medicines; thus, more usage of biomarker technology is being observed within the country.
- With more funds going toward the development of technologies like liquid biopsy, artificial intelligence diagnostics, and NGS, there has been significant growth in the market for cancer biomarkers in Japan.
Download the eBook (ToC)
Why Buy This Report
- Get a more rounded picture of the Japan cancer biomarkers market, which is including things like market size, growth patterns, competitive scene, and a future outlook analysis that helps drive precision oncology as a whole, you know.
- Look into why the demand is climbing for genomic testing, liquid biopsy solutions, molecular diagnostics, and those personalized cancer treatment options across hospitals, diagnostic laboratories and research institutes in Japan. It’s a kind of domino effect.
- Pinpoint where the fastest investment momentum is happening and which opportunities are forming, by doing a detailed look at technological advancements, product innovations, healthcare trends, and strategic developments that are really shaping the Japan cancer biomarkers sector right now.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Cancer Biomarkers market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment Market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the Market.
Top Companies in Japan Cancer Biomarkers Market
- Roche Diagnostics
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- QIAGEN N.V.
- Abbott Laboratories
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Sysmex Corporation
- Fujirebio Holdings Inc.
- Siemens Healthineers AG
- Other
Recent Developments:
- In April 2025, major biotechnology and diagnostics companies in Japan increased investments in liquid biopsy technologies and AI-integrated cancer diagnostic platforms to improve early cancer detection and precision treatment capabilities.
Market Segmentation:
Japan Cancer Biomarkers Market, By BiomarkerType
- Genetic Biomarkers
- Protein Biomarkers
- Metabolic Biomarkers
- Others
Japan Cancer Biomarkers Market, By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Others
Japan Cancer Biomarkers Market, By End User
- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Pharmaceutical Companies
- Others
Expert Views:
The Japan cancer biomarkers market is expected to witness substantial growth in the coming years owing to increasing cancer prevalence, rising adoption of precision medicine, advancements in molecular diagnostics technologies, and growing demand for early cancer detection solutions. Moreover, government initiatives supporting oncology research and personalized healthcare are expected to provide ample growth opportunities for market players in Japan.
Author: Sanket and Pranali By Spherical Insights and Consulting